Episode

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3

Podcast: Hematologic Oncology Update
Published: Sep 6, 2026
Duration seconds: 1378
Processing state: not_requested
Canonical source: https://hematologic-oncology.captivate.fm/episode/5961-cllmicro2025-5mjc-3
Audio: https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/a01d0b0e-8405-4c09-a3fb-3b6d9e6c1f33.mp3
JSON: /v1/public/podcasts/hematologic-oncology-update-916423/episodes/chronic-lymphocytic-leukemia-5-minute-journal-club-microlearning-activity-3
Markdown: /podcast/hematologic-oncology-update-916423/chronic-lymphocytic-leukemia-5-minute-journal-club-microlearning-activity-3.md

Actions

POST https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/chronic-lymphocytic-leukemia-5-minute-journal-club-microlearning-activity-3/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/hematologic-oncology-update-916423/chronic-lymphocytic-leukemia-5-minute-journal-club-microlearning-activity-3.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Featuring perspectives from Prof John Seymour, including the following topics: Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00) Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21) First-line treatment with sonrotoclax and zanubrutinib for CLL (13:10) CME information and select publications